Luis Paz‐Ares

93.4k total citations · 15 hit papers
690 papers, 23.0k citations indexed

About

Luis Paz‐Ares is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Luis Paz‐Ares has authored 690 papers receiving a total of 23.0k indexed citations (citations by other indexed papers that have themselves been cited), including 523 papers in Oncology, 445 papers in Pulmonary and Respiratory Medicine and 179 papers in Molecular Biology. Recurrent topics in Luis Paz‐Ares's work include Lung Cancer Treatments and Mutations (375 papers), Lung Cancer Research Studies (235 papers) and Cancer Immunotherapy and Biomarkers (167 papers). Luis Paz‐Ares is often cited by papers focused on Lung Cancer Treatments and Mutations (375 papers), Lung Cancer Research Studies (235 papers) and Cancer Immunotherapy and Biomarkers (167 papers). Luis Paz‐Ares collaborates with scholars based in Spain, United States and Germany. Luis Paz‐Ares's co-authors include Yi‐Long Wu, Fred R. Hirsch, Giorgio V. Scagliotti, Walter J. Curran, James L. Mulshine, Regina Kwon, Irene Ferrer, Rocio García‐Carbonero, Sonia Molina‐Pinelo and Amancio Carnero and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Luis Paz‐Ares

655 papers receiving 22.5k citations

Hit Papers

Lung cancer: current therapies and new targeted treatments 2011 2026 2016 2021 2016 2016 2018 2011 2012 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lung cancer: current therapies and new targeted treatments
    2016 2.5k citations Luis Paz‐Ares et al. profile →
  2. Current Challenges in Cancer Treatment
    2016 656 citations Sonia Molina‐Pinelo, Luis Paz‐Ares et al. profile →
  3. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
    2018 518 citations Byoung Chul Cho, Luis Paz‐Ares et al. Annals of Oncology profile →
  4. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
    2011 453 citations Robert Pirker, Jose R. Pereira et al. The Lancet Oncology profile →
  5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
    2012 447 citations Luis Paz‐Ares, Filippo de Marinis et al. The Lancet Oncology profile →
  6. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
    2013 438 citations Luis Paz‐Ares, Filippo de Marinis et al. Journal of Clinical Oncology profile →
  7. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
    2020 409 citations Luis Paz‐Ares, Héctor Soto Parrà et al. Journal of Thoracic Oncology profile →
  8. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    2017 398 citations Luis Paz‐Ares, Kenneth J. O’Byrne et al. Annals of Oncology profile →
  9. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
    2019 305 citations Takayasu Kurata, Ki Hyeong Lee et al. Journal of Thoracic Oncology profile →
  10. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
    2023 233 citations Julien Mazières, Ying Cheng et al. Journal of Clinical Oncology profile →
  11. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
    2022 144 citations Luis Paz‐Ares, Pilar Garrido et al. profile →
  12. New promises and challenges in the treatment of advanced non-small-cell lung cancer
    2024 116 citations Luis Paz‐Ares et al. profile →
  13. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
    2023 89 citations James Chih‐Hsin Yang, Luis Paz‐Ares et al. profile →
  14. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
    2023 84 citations Jon Zugazagoitia, Luis Paz‐Ares et al. profile →
  15. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
    2024 76 citations Kazuhiko Nakagawa, Luis Paz‐Ares et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luis Paz‐Ares Spain 73 13.2k 11.4k 7.6k 4.2k 2.3k 690 23.0k
Suresh S. Ramalingam United States 74 15.5k 1.2× 14.5k 1.3× 8.8k 1.2× 4.2k 1.0× 1.4k 0.6× 593 25.5k
Byoung Chul Cho South Korea 70 13.2k 1.0× 12.9k 1.1× 5.7k 0.7× 3.2k 0.8× 2.2k 0.9× 689 19.8k
Giampaolo Tortora Italy 69 13.8k 1.0× 7.8k 0.7× 9.9k 1.3× 4.8k 1.1× 2.5k 1.1× 639 24.4k
Kenneth J. O’Byrne Australia 72 12.7k 1.0× 10.5k 0.9× 8.4k 1.1× 5.0k 1.2× 1.5k 0.6× 598 23.7k
Julian R. Molina United States 44 10.5k 0.8× 8.2k 0.7× 6.2k 0.8× 3.3k 0.8× 1.4k 0.6× 216 18.3k
Benjamin Solomon Australia 61 12.7k 1.0× 14.1k 1.2× 6.7k 0.9× 4.3k 1.0× 1.5k 0.7× 415 20.8k
Keunchil Park South Korea 75 17.9k 1.4× 17.0k 1.5× 6.2k 0.8× 4.0k 0.9× 2.7k 1.1× 567 27.4k
Fabrice Barlési France 65 15.4k 1.2× 13.4k 1.2× 5.1k 0.7× 3.3k 0.8× 1.1k 0.5× 570 22.1k
Federico Cappuzzo Italy 63 16.9k 1.3× 16.9k 1.5× 7.0k 0.9× 4.3k 1.0× 1.5k 0.6× 360 24.6k
Mark A. Socinski United States 69 15.1k 1.1× 14.6k 1.3× 4.9k 0.6× 3.0k 0.7× 1.2k 0.5× 518 22.3k

Countries citing papers authored by Luis Paz‐Ares

Since Specialization
Citations

This map shows the geographic impact of Luis Paz‐Ares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Paz‐Ares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Paz‐Ares more than expected).

Fields of papers citing papers by Luis Paz‐Ares

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Paz‐Ares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Paz‐Ares. The network helps show where Luis Paz‐Ares may publish in the future.

Co-authorship network of co-authors of Luis Paz‐Ares

This figure shows the co-authorship network connecting the top 25 collaborators of Luis Paz‐Ares. A scholar is included among the top collaborators of Luis Paz‐Ares based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Paz‐Ares. Luis Paz‐Ares is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cabo, Horacio, Esther Conde, Susana Hernández, et al.. (2024). Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC. JTO Clinical and Research Reports. 6(3). 100778–100778.
2.
Italiano, Antoine, Hossein Borghaei, Sanjay Popat, et al.. (2024). 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study. Immuno-Oncology Technology. 24. 100747–100747. 3 indexed citations
3.
Paz‐Ares, Luis, Shobhit Baijal, Pilar Garrido, et al.. (2024). 1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC). Annals of Oncology. 35. S836–S838. 1 indexed citations
4.
Gadgeel, Shirish M., Delvys Rodríguez‐Abreu, Balázs Halmos, et al.. (2024). Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. Journal of Thoracic Oncology. 19(8). 1228–1241. 19 indexed citations
5.
Agulló-Ortuño, M. Teresa, Esther Mancebo, Montserrat Grau, et al.. (2023). Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models. International Journal of Molecular Sciences. 24(16). 13005–13005. 9 indexed citations
6.
Hernández, Susana, Esther Conde, Marta Alonso de la Varga, et al.. (2023). A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma. Translational Lung Cancer Research. 12(7). 1549–1562. 8 indexed citations
7.
8.
Arriola, Edurne, M.R. García-Campelo, Margarita Majem, et al.. (2023). 1993P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results. Annals of Oncology. 34. S1063–S1063. 3 indexed citations
9.
Nakagawa, Kazuhiko, Ernest Nadal, Edward B. Garon, et al.. (2021). RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 27(19). 5258–5271. 29 indexed citations
10.
Aix, Santiago Ponce, Enric Carcereny, Joaquim Bosch‐Barrera, et al.. (2021). 160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I. Annals of Oncology. 32. S1450–S1450. 5 indexed citations
11.
Majem, Margarita, Manuel Cobo, Dolores Isla, et al.. (2021). PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. Journal of Clinical Medicine. 10(7). 1365–1365. 15 indexed citations
12.
Yu, Helena A., Luis Paz‐Ares, James Chih‐Hsin Yang, et al.. (2020). Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non–small Cell Lung Cancer. Clinical Cancer Research. 27(4). 992–1002. 31 indexed citations
13.
Münster, Pamela N., Monica Mita, Amit Mahipal, et al.. (2019). First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. SHILAP Revista de lepidopterología. 1 indexed citations
14.
Kim, Edward S., Karen Kelly, Luis Paz‐Ares, et al.. (2018). Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study. Clinical Cancer Research. 24(22). 5543–5551. 17 indexed citations
15.
Spigel, David R., Martin J. Edelman, Kenneth J. O’Byrne, et al.. (2017). Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung. Journal of Clinical Oncology. 35(4). 412–420. 232 indexed citations
16.
Bédard, Philippe L., Josep Tabernero, Filip Jankú, et al.. (2014). A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clinical Cancer Research. 21(4). 730–738. 257 indexed citations
17.
Rodón, Jordi, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez, et al.. (2014). First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clinical Cancer Research. 21(3). 553–560. 200 indexed citations
18.
Estévez-García, Purificación, Sonia Molina‐Pinelo, Sandra Muñoz-Galván, et al.. (2013). Spinophilin Loss Correlates with Poor Patient Prognosis in Advanced Stages of Colon Carcinoma. Clinical Cancer Research. 19(14). 3925–3935. 15 indexed citations
19.
Pirker, Robert, Jose R. Pereira, Joachim von Pawel, et al.. (2011). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. The Lancet Oncology. 13(1). 33–42. 453 indexed citations breakdown →
20.
Aparicio, Jorge, J.R. Germà, Xavier García del Muro, et al.. (2005). Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study. Journal of Clinical Oncology. 23(34). 8717–8723. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suresh S. Ramalingam Breakdown of academic impact, for papers by Byoung Chul Cho Breakdown of academic impact, for papers by Giampaolo Tortora Breakdown of academic impact, for papers by Kenneth J. O’Byrne Breakdown of academic impact, for papers by Julian R. Molina Breakdown of academic impact, for papers by Benjamin Solomon Breakdown of academic impact, for papers by Keunchil Park Breakdown of academic impact, for papers by Fabrice Barlési Breakdown of academic impact, for papers by Federico Cappuzzo Breakdown of academic impact, for papers by Mark A. Socinski
Rankless by CCL
2026